Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales

Jazz Pharmaceuticals

03/08/2026 21:24

Overview
Ireland biopharma firm's Q2 revenue rose 16% yr/yr, beating analyst expectations
Adjusted EPS for Q2 missed analyst expectations
Company raised 2026 revenue guidance after strong first half

Outlook
Jazz raises 2026 revenue guidance to $4.60-$4.75 bln 
Company expects 2026 non-GAAP gross margin of 90%-91% and effective tax rate of 11.5%-13.5%
Jazz prepared to launch Ziihera in HER2+ 1L GEA after expected FDA approval (PDUFA date August 25, 2026)

Result Drivers
XYWAV PATIENT GROWTH - Co said Xywav sales rose 13% YoY in Q2, driven by 525 net patient adds and continued physician and patient demand for low-sodium formulation
EPIDIOLEX DEMAND - Epidiolex/Epidyolex sales grew 16% YoY in Q2, attributed to continued strong demand and expanded clinical development
ZEPZELCA UPTAKE - Zepzelca sales increased 42% YoY in Q2, supported by continued uptake in first-line maintenance ES-SCLC, partially offset by decline in second-line use

Company press release: ID:nPn28gXtma

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.21 bln
$1.12 bln (15 Analysts)
Q2 Adjusted EPS
Miss
$5.71
$6.18 (17 Analysts)
Q2 EPS
 
$2.78
 
Q2 Adjusted Net Income
Miss
$396.40 mln
$410.26 mln (13 Analysts)
Q2 Net Income
 
$192.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $275.00, about 8.8% above its July 31 closing price of $252.86
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads
Aug 3 - Vertex raises annual revenue forecast on cystic fibrosis drugs strength 
Aug 3 - Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
Aug 3 - Krystal Biotech Q2 revenue rises on VYJUVEK strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)